Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

Revive Therapeutics (QB) (RVVTF)

Revive Therapeutics Ltd (QB)
Date:
Sort by:
 Showing the most relevant articles for your search:USOTC:RVVTF
DateTimeSourceHeadlineSymbolCompany
18/04/202215:26InvestorsHub NewsWireRevive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
12/04/202213:00InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
29/03/202214:57InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
24/02/202213:35InvestorsHub NewsWireHAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical ResearchUSOTC:RVVTFRevive Therapeutics Ltd (QB)
16/02/202213:03InvestorsHub NewsWireRevive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver TransplantationUSOTC:RVVTFRevive Therapeutics Ltd (QB)
14/02/202211:53InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
19/01/202213:19InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
17/01/202214:13InvestorsHub NewsWireRevive Therapeutics Provides Update of Psilocybin Pharmaceutical ProgramsUSOTC:RVVTFRevive Therapeutics Ltd (QB)
07/01/202213:05InvestorsHub NewsWireRevive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
16/11/202113:00InvestorsHub NewsWireRevive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta VariantUSOTC:RVVTFRevive Therapeutics Ltd (QB)
22/09/202112:30InvestorsHub NewsWireRevive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETFUSOTC:RVVTFRevive Therapeutics Ltd (QB)
18/08/202111:00InvestorsHub NewsWireRevive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat CancerUSOTC:RVVTFRevive Therapeutics Ltd (QB)
12/08/202114:56InvestorsHub NewsWireRevive Confirms No Material Undisclosed InformationUSOTC:RVVTFRevive Therapeutics Ltd (QB)
10/08/202113:52InvestorsHub NewsWireRevive Therapeutics Provides Update on Psychedelics Clinical Product PipelineUSOTC:RVVTFRevive Therapeutics Ltd (QB)
15/07/202119:47InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trialfor Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
28/06/202113:00InvestorsHub NewsWireRevive Therapeutics Approved to Trade on the OTCQB MarketUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/06/202113:59InvestorsHub NewsWireRevive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of PsychedelicsUSOTC:RVVTFRevive Therapeutics Ltd (QB)
08/06/202114:12InvestorsHub NewsWireRevive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in IndiaUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/05/202114:48InvestorsHub NewsWireRevive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film StripUSOTC:RVVTFRevive Therapeutics Ltd (QB)
03/05/202114:32InvestorsHub NewsWireRevive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
27/04/202114:51InvestorsHub NewsWireRevive Therapeutics Files For FDA Orphan Drug Designation for Psilocybin in Traumatic Brain InjuryUSOTC:RVVTFRevive Therapeutics Ltd (QB)
22/04/202113:26InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....contUSOTC:RVVTFRevive Therapeutics Ltd (QB)
24/03/202113:15InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
19/03/202111:56InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of ...ContUSOTC:RVVTFRevive Therapeutics Ltd (QB)
26/02/202114:01InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion...ContUSOTC:RVVTFRevive Therapeutics Ltd (QB)
26/02/202114:01InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion...ContUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/02/202114:53InvestorsHub NewsWireRevive Therapeutics Acquires Unique Psilocybin AssetsUSOTC:RVVTFRevive Therapeutics Ltd (QB)
11/02/202113:05InvestorsHub NewsWireRevive Therapeutics Provides Update on Cannabinoid Pharmaceuticals ProgramUSOTC:RVVTFRevive Therapeutics Ltd (QB)
27/01/202113:13InvestorsHub NewsWireRevive Therapeutics in Phase 3 clinical trial for COVID-19 treatmentUSOTC:RVVTFRevive Therapeutics Ltd (QB)
18/01/202114:51InvestorsHub NewsWireHow Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain InjuriesUSOTC:RVVTFRevive Therapeutics Ltd (QB)
 Showing the most relevant articles for your search:USOTC:RVVTF